HG 303
Alternative Names: HG-303Latest Information Update: 03 Jun 2024
At a glance
- Originator HuidaGene Therapeutics
- Class Gene therapies
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 29 May 2024 Preclinical trials in Amyotrophic lateral sclerosis in China (Parenteral), prior to May 2024
- 12 Sep 2023 Amyotrophic lateral sclerosis therapy - HuidaGene Therapeutics is available for licensing as of 12 Sep 2023. https://www.huidagene.com/licensing
- 12 Sep 2023 Early research in Amyotrophic lateral sclerosis in China, prior to September 2023 (Parenteral) (Huidagene Therapeutics pipeline, September 2023)